Debate: Will chemotherapy continue to be standard treatment for symptomatic mCRPC in the era of novel agents? (for)

Lecture: Clinical Perspectives: How far are we from personalising treatment for prostate cancer patients?

Debate: Will chemotherapy continue to be standard treatment for symptomatic mCRPC in the era of novel agents? (against)

Lecture: Future strategies and targets for prostate cancer

Rituximab versus idelalisib in refractory CLL

Use of GA101 and Clb preferable to rituximab in elderly or unfit chronic lymphocytic leukaemia patients

WIN Symposium 2014: Breakthrough biomarker investigations and combination therapies

Intratumour heterogeneity in renal and lung cancer

High levels of mutated p53 indicate metastatic phenotype

New drug OTX15 shows early promise in fighting acute myeloid leukaemia

Personalisation of leukaemia treatment using genome sequencing

Subset of breast cancer patients found to benefit from neratinib in latest trial